A Randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans

Charles H. Hennekens, Wendy R. Schneider, Alex Pokov, Scott Hetzel, David Demets, Victor Serebruany, Henning Schröder

Research output: Contribution to journalArticlepeer-review

Abstract

Background: We performed the first test in humans of whether aspirin at clinically relevant doses increases nitric oxide (NO) formation. Methods: Seventy primary prevention patients with metabolic syndrome were randomly assigned to 81 mg, 162.5 mg, 325 mg, 650 mg, or 1300 mg aspirin daily for 12 weeks to test changes in heme oxygenase (HO-1), a downstream target of NO formation and asymmetrical dimethylarginine (ADMA), a competitive inhibitor of NO synthase. Findings: For HO-1, the mean was 29.37 nanograms per milliliter at baseline and 57.45 at 12 weeks giving a mean ratio (MR) of 1.96 (P

Original languageEnglish (US)
Pages (from-to)344-348
Number of pages5
JournalJournal of Cardiovascular Pharmacology and Therapeutics
Volume15
Issue number4
DOIs
StatePublished - Dec 2010
Externally publishedYes

Keywords

  • atherosclerosis
  • cardiovascular disease
  • endothelium
  • thrombosis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'A Randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans'. Together they form a unique fingerprint.

Cite this